AGITG and Scandinavian Sarcoma Group International Trial Collaboration. SSG XXII: International randomised phase III multicenter study of 3 v 5 years of adjuvant imatinib as treatment of patients with operable GIST with high risk for recurrence.

The Scandinavian Sarcoma Group (SSG) SSGXXII Study, is a randomised phase III multicentre study of three years versus five years of adjuvant imatinib as treatment of patients with an operable, gastrointestinal stromal tumour (GIST), at high risk* for recurrence. (*High risk is defined as Gastric GIST with >10 mitoses/50 HPFs; or non-gastric GIST with >5 mitoses/50 HPFs; or non gastric GIST treated with neoadjuvant imatinib and initially larger than 10 cm; or tumour rupture.) In conjunction with the International Trial Management Committee (ITMC) and the Australian chief investigators of this application, we believe the collaboration by the Australasian Gastro Intestinal Trials Group (AGITG) in partnership with the NHMRC Clinical Trials Centre (CTC) and SSG for this Phase III Study meets the expected (a) outcomes and (b) objectives of the MRFF ICTC scheme.